{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"jRCT2080225166","nct_id":"NCT04195750","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=jrct2080225166-nct04195750. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.","label":"Belzutifan","type":"EXPERIMENTAL"},{"description":"Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.","label":"Everolimus","type":"ACTIVE_COMPARATOR"},{"description":"Non-Randomized participants enrolled into the Safety Run-in received up to 120 mg of belzutifan QD.","label":"Safety Run-In","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-10-14","type":"ESTIMATED"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":755,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Belzutifan","otherNames":["MK-6482","WELIREG™"],"type":"DRUG"},{"name":"Everolimus","otherNames":["Afinitor","Afinitor DISPERZ","Zortress"],"type":"DRUG"}],"last_update":"2026-10-20","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-04-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 39 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 49 months"}],"references":[{"citation":"Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gumus M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906.","pmid":"39167807","type":"RESULT"},{"citation":"Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gumus M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B. Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr;26(4):491-502. doi: 10.1016/S1470-2045(25)00032-4. Epub 2025 Mar 17.","pmid":"40112850","type":"DERIVED"}],"start_date":{"date":"2020-02-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)","url":"https://clinicaltrials.gov/study/NCT04195750"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/jrct2080225166-nct04195750"}